Adherence: The Furnace Filter Analogy

Pharmacy Times, Volume 0, 0

If you ask furnace repairmen todescribe the greatest frustration ofthe trade, you will hear a familiarstory. Even though the repairmenremind people and offer ways for themto remember, most people fail to cleanor replace their furnace filters monthly.If people do remember, they may notdo the job correctly or well. That problemsounds similar to a problem thathealth care providers face every day:medication and treatment adherence.Consider these facts:

More than 29% of adults have hypertension(HTN)1,2 and are at increasedrisk for adverse outcomes. Althougheffective treatment reduces risk,3,4most patients with HTN have poorlycontrolled blood pressure,5,6 and up to70% of patients are nonadherent withprescription medication.1,7-9

Among diabetics treated with sulfonylureas,adherence is estimated tobe as low as 10% to 50%.10

Among HIV-infected people, high-leveladherence (in the range of 90% to95% of doses taken correctly) is necessaryto prevent viral resistance and toimprove immunologic, virologic, andclinical outcomes. Regardless, adherenceoften is reported to be less than70%.11

Most pharmacists know some of thefactors that increase the risk of nonadherence:

  • Increasing numbers of drugs anddoses
  • Difficult administration routes ortiming
  • Silent or symptomless diseases
  • Cost of medications
  • Intolerable side effects

In the past, health care clinicianshave used patient self-report, clinicianimpression, pill counts, pharmacologictracers, and electronic measurementdevices to assess adherence. Examinationof pharmacy claims data is arecent method that allows access toaggregate data on medication dosingand refill patterns. The new buzzwordis medication possession ratio(MPR),12,13 which now is used frequentlyas an adherence measure.10,12-25 (seesidebar).

Poor medication adherence is differentfrom poor furnace filter maintenancein that furnace repairmen do nothave aggregated statistics about nonadherenceas pharmacists do. Ultimately,statistics do not create changein and of themselves, and direct-careclinicians have to intervene. Medicationadherence and furnace filtermaintenance are similar in that accessand cost can be barriers, and culturalbeliefs or misinformation also may beimportant.

Hypertensive patients, for example,often indicate that they become nonadherentbecause they believe thatthey are cured (46%), or they perceivethat their prescribing clinician directedthem to stop (25%).26 Patients may forgetto take medications, misunderstandwhen or how to take them, takeextra doses to treat stubborn symptoms,or consciously decide to stoptaking medications.27 Clinicians may beignorant of these problems and mayinterpret unidentified nonadherence aspoor drug effectiveness.

Communication technique is key toimproving adherence, especially communicationthat employs a patient-centeredapproach that allows patientsto participate in shared decision making.28-31 Unfortunately, physicians rarelyengage patients in decision making:often they just inform patients of theneed for medication.30 They also areunlikely to question patients aboutmedication-taking behaviors.32

Changing Behavior

Clinicians cannot expect to changepatient behaviors without first knowingcurrent medication-taking behaviors.Asking questions is the cornerstone ofthe approach, and most communicationexperts recommend using directand information-intensive approachesto assessing adherence.33 Despite decades of education directed at healthcare providers to improve communication,providers frequently use inappropriatestructure, temporality, content,and style when asking patients aboutadherence.34

The structure of a question eitherpromotes or inhibits the amount andkind of information sharing frompatients. Patients will respond toclosed-ended questions with a simpleyes or no, rarely venturing any additionalinformation. Declarative questions(eg, "You take your medication,right?") also squelch patients' propensityto volunteer extensive information.Patients are not being intentionally dishonest;instead they engage in thehuman tendency to be agreeable. (Mylast furnace repairperson used to say,"You change your filter monthly, right?"Of course, I agreed.)

Switching to a subtly interrogative,open-ended question approach thatuses question strings allows collaborationand also permits patients to verbalizeconcerns and beliefs. Pharmacistscan say, "Tell me how you takethis prescription," and then help thepatient see how to improve. The resultshould improve adherence.34

Providers also need to simplify theircommunication. Asking about medicationsby pharmaceutical or tradenames can confuse some patients.Describing tablet or capsule color andsize can prompt better responses,especially for patients with low healthliteracy.35,36 Confrontational communicationstyles will tend to make patientsdefensive and will erode potentialprovider-patient therapeutic alliances(eg, "Didn't I tell you to take it in themorning on an empty stomach?").37,38Providers who insist on communicationthat transfers information to thepatient rather than exchanges informationcollaboratively miss an opportunityto improve adherence.39-41

In addition to communication barriers,patients' beliefs about medication alsomay contribute to problems with communicatingabout medication taking.42Demographics such as age, gender, race,intelligence, level of education, maritalstatus, and social status generally do notcontribute to or affect adherence. Elders' adherence problems usually arerelated more closely to the medicationregimen's characteristics than to ageitself. Limited access to health care,financial problems, and lack of socialsupport can undermine adherence.43

End Note

My furnace repairperson cajoled meinto being more adherent to my furnacemaintenance schedule. He pointedout barriers (poor location, dirtyjob); factors that increased my risk ofpoor outcome (multiple animals in thehouse); and the inevitable outcome if Ifailed to adhere (costly furnacerepairs). He taught me ways to remember(put a note in with my bills payable,ask for help from family members).Then, he stuck out his hand to shakeand said, "Promise you'll do better." Weestablished an informal "contract," andmy adherence is better.

Try a similar approach when youcounsel patients about improvingadherence, but realize that the patientswith whom you can expect to see thebest return on investment are thosethat are mildly to moderately nonadherent.Do not expect to changepatients who are completely nonadherentinto adherence stars. Nevertheless,do not let a counseling opportunitypass you by. It may very well bethe one that may promote some positivechange.

Ms. Wick is a senior clinical researchpharmacist at the National CancerInstitute, National Institutes ofHealth, Bethesda, Md. The viewsexpressed are those of the authorand not those of any governmentagency.

References

1. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.

2. Chobanian A, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.

3. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349-1354.

4. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.

5. Jamerson K, DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med. 1996;101:22S-32S.

6. Winickoff R, Murphy PK. The persistent problem of poor blood pressure control. Arch Intern Med. 1987;147:1393-1396.

7. Management of patient compliance in the treatment of hypertension: report of the NHLBI Working Group. Hypertension. 1982;4:415-423.

8. Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, MD: Johns Hopkins University Press; 1979:11-22.

9. Clark LT. Improving compliance and increasing control of hypertension: needs of special hypertensive populations. Am Heart J. 1991;121(suppl):664.

10. Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race. Diabetes Educ. 1999;25:531-538.

11. Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20:418-428.

12. Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther. 1991;13:489-495.

13. Sclar DA, Skaer TL, Chin A, Okamoto MP, Gill MA. Utility of a transdermal delivery system for antihypertensive therapy: Pt 2. Am J Med. 1991;91:57S-60S.

14. Skaer TL, Sclar DA, Markowski DJ, Won JK. Effect of value-added utilities on prescription refill compliance and Medicaid health care expenditures?a study of patients with non-insulin-dependent diabetes mellitus. J Clin Pharm Ther. 1993;18:295-299.

15. Skaer TL, Sclar DA, Markowski DJ, Won JK. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. J Hum Hypertens. 1993;7:515-518.

16. Skaer TL, Sclar DA, Markowski DJ, Won JK. Utility of a sustained-release formulation for antihypertensive therapy. J Hum Hypertens. 1993;7:519-522.

17. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res. 1995;23:395-412.

18. Okano GJ, Rascati KL, Wilson JP, Remund DD, Grabenstein JD, Brixner DI. Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker. Clin Ther. 1997;19:1433-1445.

19. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.

20. Hurley JS, Frost EJ, Trinkaus KM, Buatti MC, Emmett KE. Relationship of compliance with hormone replacement therapy to short-term healthcare utilization in a managed care population. Am J Manag Care. 1998;4:1691-1698.

21. Blanford L, Dans PE, Ober JD, Wheelock C. Analyzing variations in medication compliance related to individual drug, drug class, and prescribing physician. J Manag Care Pharm. 1999;5:47-51.

22. Roe CM, Motheral BR, Teitelbaum F, Rich MW. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J. 1999;138:818-825.

23. Lawrence M, Guay DRP, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy. 2000;20:470-475.

24. Xuan J, Duong PT, Russo PA, Lacey MJ, Wong B. The economic burden of congestive heart failure in a managed care population. Am J Manag Care. 2000;6:693-700.

25. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449-457.

26. Gallup G Jr, Cotugno HE. Preferences and practices of Americans and their physicians in antihypertensive therapy. Am J Med. 1986;81:20-24.

27. Horne R, Clatworthy J, Polmear A, Weinman J. Do hypertensive patients' beliefs about their illness and treatment influence medication adherence and quality of life? J Hum Hypertension. 2001;15(suppl 1):S65-S68.

28. Theunissen NC, de Ridder DT, Bensing JM, Rutten GE. Manipulation of patient-provider interaction: discussing illness representations or action plans concerning adherence. Patient Educ Couns. 2003;51:247-258.

29. Ogedegbe G, Harrison M, Robbins L, Mancuso CA, Allegrant JP. Barriers and facilitators of medication adherence in hypertensive African Americans: a qualitative study. Ethn Dis. 2004;14:3-12.

30. Stevenson FA, Barry C, Britten N, Barber N, Bradley CP. Doctor-patient communication about drugs: the evidence for shared decision making. Soc Sci Med. 2000;50:829-840.

31. Ockene JK, Kristeller J, Goldberg R, et al. Increasing the efficacy of physician-delivered smoking interventions: a randomized clinical trial. J Gen Intern Med. 1991;6:1-8.

32. Kjellgren KI, Svensson S, Ahlner J, Saljo R. Antihypertensive medication in clinical encounters. Int J Cardiol. 1998;64:161-169.

33. Steele DJ, Jackson TC, Gutmann MC. Have you been taking your pills? The adherence-monitoring sequence in the medical interview. J Fam Pract. 1990;30:294-299.

34. Bokhour BG, Berlowitz DR, Long JA, Kressin NR. How do providers assess antihypertensive medication adherence in medical encounters? J Gen Intern Med. 2006;21:577-583.

35. Baker DW, Parker RM, Williams MV, et al. The health care experience of patients with low literacy. Arch Fam Med. 1996;5:329-334.

36. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med. 1999;14:267-273.

37. Mead M, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 2000;51:1087-1110.

38. Kjellgren KI, Ahlner J, Saljo R. Taking antihypertensive medication?controlling or co-operating with patients? Int J Cardiol. 1995;47:257-268.

39. Braddock CH 3rd, Edwards KA, Hasenberg NM, Laidley TL, Levinson W. Informed decision making in outpatient practice: time to get back to basics. JAMA. 1999;282:2313-2320.

40. Frankel RM, Terry S. Getting the most out of the clinical encounter: the four habits model. Permanente J. 1999;3(3):1-8.

41. Lee R, Garvin T. Moving from information transfer to information exchange in health and health care. Soc Sci Med. 2003;56:449-464.

42. Ong LM, de Haes JC, Hoos AM, Lammes FB. Doctor-patient communication: a review of the literature. Soc Sci Med. 1995;40:903-918.

43. American Pharmacists Association. Medication Compliance-Adherence-Persistence (CAP) Digest. Washington, DC: APhA and Pfizer Pharmaceuticals; 2003.